RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

BACKGROUND: RET fusions are rare oncogenic drivers in non-small cell lung cancer (NSCLC). While activating RET rearrangements are found in NSCLC patients harboring epidermal growth factor receptor (EGFR) genetic alterations at resistance to EGFR inhibitors, the extent to which co-occurring genomic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chunyue, Zhang, Zhenlong, Sun, Yulan, Wang, Song, Wu, Mengmeng, Ou, Qiuxiang, Xu, Yang, Chen, Zhiming, Shao, Yang, Liu, Hong, Hou, Peifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441062/
https://www.ncbi.nlm.nih.gov/pubmed/36059009
http://dx.doi.org/10.1186/s12967-022-03593-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441062/
https://www.ncbi.nlm.nih.gov/pubmed/36059009
http://dx.doi.org/10.1186/s12967-022-03593-3

Ejemplares similares